8.31
-0.40 (-4.59%)
| Previous Close | 8.71 |
| Open | 8.80 |
| Volume | 240,247 |
| Avg. Volume (3M) | 306,260 |
| Market Cap | 490,486,144 |
| Price / Sales | 279.93 |
| Price / Book | 6.58 |
| 52 Weeks Range | |
| Earnings Date | 1 Aug 2024 - 5 Aug 2024 |
| Operating Margin (TTM) | -4,095.46% |
| Diluted EPS (TTM) | -3.57 |
| Quarterly Revenue Growth (YOY) | 179.90% |
| Total Debt/Equity (MRQ) | 32.18% |
| Current Ratio (MRQ) | 7.07 |
| Operating Cash Flow (TTM) | -167.92 M |
| Levered Free Cash Flow (TTM) | -109.28 M |
| Return on Assets (TTM) | -35.99% |
| Return on Equity (TTM) | -115.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | IGM Biosciences, Inc. | Bearish | Bullish |
Stockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | 3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.5 |
| Average | 0.00 |
|
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 35.27% |
| % Held by Institutions | 66.33% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 22.00 (Wedbush, 164.74%) | Buy |
| Median | 14.50 (74.49%) | |
| Low | 9.00 (JP Morgan, 8.30%) | Sell |
| Average | 15.17 (82.55%) | |
| Total | 3 Buy, 2 Hold, 1 Sell | |
| Avg. Price @ Call | 13.79 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 01 Oct 2024 | 20.00 (140.67%) | Buy | 14.50 |
| JP Morgan | 01 Oct 2024 | 9.00 (8.30%) | Sell | 14.50 |
| 15 Aug 2024 | 12.00 (44.40%) | Hold | 9.27 | |
| RBC Capital | 01 Oct 2024 | 17.00 (104.57%) | Buy | 14.50 |
| 15 Aug 2024 | 20.00 (140.67%) | Buy | 9.27 | |
| Truist Securities | 01 Oct 2024 | 12.00 (44.40%) | Hold | 14.50 |
| 23 Aug 2024 | 24.00 (188.81%) | Buy | 10.45 | |
| Wedbush | 01 Oct 2024 | 22.00 (164.74%) | Buy | 14.50 |
| 15 Aug 2024 | 25.00 (200.84%) | Buy | 9.27 | |
| HC Wainwright & Co. | 05 Sep 2024 | 11.00 (32.37%) | Hold | 10.25 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 16.54 | - | 3,988 | 65,962 |
| BEHRENS M KATHLEEN | 16.54 | - | 3,078 | 50,910 |
| LEE MICHAEL STEWART | 16.54 | - | 1,734 | 28,680 |
| REDMILE GROUP, LLC | 16.54 | - | 1,734 | 28,680 |
| THOMPSON ELIZABETH H.Z. | 16.54 | - | 1,452 | 24,016 |
| TOPSOE CHRISTINA TENG | 16.54 | - | 2,687 | 44,443 |
| TOPSOE JAKOB HALDOR | 16.54 | - | 1,734 | 28,680 |
| Aggregate Net Quantity | 16,407 | |||
| Aggregate Net Value ($) | 271,372 | |||
| Aggregate Avg. Buy ($) | 16.54 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Director | 30 Sep 2024 | Acquired (+) | 3,988 | 16.54 | 65,962 |
| BEHRENS M KATHLEEN | Director | 30 Sep 2024 | Acquired (+) | 3,078 | 16.54 | 50,910 |
| THOMPSON ELIZABETH H.Z. | Director | 30 Sep 2024 | Acquired (+) | 1,452 | 16.54 | 24,016 |
| TOPSOE CHRISTINA TENG | Director | 30 Sep 2024 | Acquired (+) | 2,687 | 16.54 | 44,443 |
| TOPSOE JAKOB HALDOR | Director | 30 Sep 2024 | Acquired (+) | 1,734 | 16.54 | 28,680 |
| LEE MICHAEL STEWART | Director | 30 Sep 2024 | Acquired (+) | 1,734 | 16.54 | 28,680 |
| REDMILE GROUP, LLC | Director | 30 Sep 2024 | Acquired (+) | 1,734 | 16.54 | 28,680 |
| Date | Type | Details |
|---|---|---|
| 30 Sep 2024 | Announcement | IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity |
| 10 Sep 2024 | Announcement | IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit |
| 14 Aug 2024 | Announcement | IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |